J Gauthier

Summary

Affiliation: Glaxo Wellcome
Country: USA

Publications

  1. ncbi Quantitation of hepatitis B viremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudine
    J Gauthier
    Department of Virology, Glaxo Wellcome, Inc, Research Triangle Park, NC 27709, USA
    J Infect Dis 180:1757-62. 1999
  2. ncbi Two sensitive PCR-based methods for detection of hepatitis B virus variants associated with reduced susceptibility to lamivudine
    M I Allen
    Department of Virology, Inc, Research Triangle Park, North Carolina 27709 3398, USA
    J Clin Microbiol 37:3338-47. 1999

Collaborators

Detail Information

Publications2

  1. ncbi Quantitation of hepatitis B viremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudine
    J Gauthier
    Department of Virology, Glaxo Wellcome, Inc, Research Triangle Park, NC 27709, USA
    J Infect Dis 180:1757-62. 1999
    ..Thus, patients who respond to lamivudine therapy with dramatic reductions in viral DNA level (to <104 genomes/mL) appear more likely to seroconvert than patients who do not achieve this level of HBV clearance...
  2. ncbi Two sensitive PCR-based methods for detection of hepatitis B virus variants associated with reduced susceptibility to lamivudine
    M I Allen
    Department of Virology, Inc, Research Triangle Park, North Carolina 27709 3398, USA
    J Clin Microbiol 37:3338-47. 1999
    ..These assays should prove useful for further understanding of virological response to therapy and disease progression...